Periostin-binding DNA aptamer treatment attenuates renal fibrosis under diabetic conditions

[1]  Abhishek Parashar,et al.  Aptamers in Therapeutics. , 2016, Journal of clinical and diagnostic research : JCDR.

[2]  S. Conway,et al.  Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. , 2014, Journal of the American Society of Nephrology : JASN.

[3]  D. Noh,et al.  Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  M. Yanagita.  Inhibitors/antagonists of TGF-β system in kidney fibrosis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  H. Lan.  Transforming growth factor‐β/Smad signalling in diabetic nephropathy , 2012, Clinical and experimental pharmacology & physiology.

[6]  S. Adler,et al.  Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  E. Rondeau,et al.  Identification of Periostin as a Critical Marker of Progression/Reversal of Hypertensive Nephropathy , 2012, PloS one.

[8]  Seonghwan Lee,et al.  Aptamers and Their Biological Applications , 2012, Sensors.

[9]  D. Hamilton,et al.  Periostin modulates myofibroblast differentiation during full-thickness cutaneous wound repair , 2012, Journal of Cell Science.

[10]  H. Moch,et al.  Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update , 2011, Virchows Archiv.

[11]  Felix Eichinger,et al.  Cardiovascular , Pulmonary , and Renal Pathology Periostin Is Induced in Glomerular Injury and Expressed de Novo in Interstitial Renal Fibrosis , 2011 .

[12]  N. Frangogiannis,et al.  TGF-β signaling in fibrosis , 2011, Growth factors.

[13]  M. Fukayama,et al.  Delayed Re-Epithelialization in Periostin-Deficient Mice during Cutaneous Wound Healing , 2011, PloS one.

[14]  K. Sharma,et al.  New pharmacological treatments for improving renal outcomes in diabetes , 2010, Nature Reviews Nephrology.

[15]  Robert H. Jenkins,et al.  Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[16]  F. Brosius,et al.  Abnormalities in signaling pathways in diabetic nephropathy , 2010, Expert review of endocrinology & metabolism.

[17]  T. Ravasi,et al.  Pirfenidone is renoprotective in diabetic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[18]  A. Ramamurthi,et al.  Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues , 2007, Journal of cellular biochemistry.

[19]  H. Sakurai,et al.  Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv‐mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib , 2006, Cancer science.

[20]  Fang Liu,et al.  Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  H. Lan,et al.  Transforming growth factor‐β and Smad signalling in kidney diseases , 2005, Nephrology.

[22]  A. Mauviel,et al.  TGF-β-induced SMAD signaling and gene regulation : consequences for extracellular matrix remodeling and wound healing , 2004 .

[23]  R. Markwald,et al.  Periostin is expressed within the developing teeth at the sites of epithelial–mesenchymal interaction , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[24]  E. Masliah,et al.  Loss of TGF-β1 Leads to Increased Neuronal Cell Death and Microgliosis in Mouse Brain , 2003, Neuron.

[25]  S. Hubchak,et al.  TGF-β signal transduction and mesangial cell fibrogenesis , 2003 .

[26]  D. Fishman,et al.  Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. , 2002, Cancer research.

[27]  T. Shimada,et al.  Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy , 2002, Medical Electron Microscopy.

[28]  J. Pouysségur,et al.  Transforming Growth Factor 1 (TGF- 1) Promotes Endothelial Cell Survival during In Vitro Angiogenesis via an Autocrine Mechanism Implicating TGF- Signaling , 2001 .

[29]  S. Adler,et al.  p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. , 2001, Kidney international.

[30]  S. Taylor,et al.  Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats , 2001, British journal of pharmacology.

[31]  R. Markwald,et al.  Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation , 2001, Mechanisms of Development.

[32]  L. Gold,et al.  Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.

[33]  M. Cooper,et al.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.

[34]  Lynda F. Bonewald,et al.  Identification and Characterization of a Novel Protein, Periostin, with Restricted Expression to Periosteum and Periodontal Ligament and Increased Expression by Transforming Growth Factor β , 1999 .

[35]  M. Fukagawa,et al.  Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats , 1997 .

[36]  Jia Guo,et al.  Neutralization of TGF-β by Anti-TGF-β Antibody Attenuates Kidney Hypertrophy and the Enhanced Extracellular Matrix Gene Expression in STZ-Induced Diabetic Mice , 1996, Diabetes.

[37]  D. Basile,et al.  Increased transforming growth factor-beta 1 expression in regenerating rat renal tubules following ischemic injury. , 1996, The American journal of physiology.

[38]  S. Nattel,et al.  Transmembrane chloride currents in human atrial myocytes. , 1996, The American journal of physiology.

[39]  K. Sharma,et al.  Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. , 1994, The American journal of physiology.

[40]  L. Fine,et al.  Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? , 1994, Kidney international.

[41]  F. Ziyadeh.  The extracellular matrix in diabetic nephropathy. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  K. Nath,et al.  Tubulointerstitial changes as a major determinant in the progression of renal damage. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  B. Chavers,et al.  Mesangial Expansion as a Central Mechanism for Loss of Kidney Function in Diabetic Patients , 1989, Diabetes.

[44]  R. Apte.  Pegaptanib sodium for the treatment of age-related macular degeneration. , 2008, Expert opinion on pharmacotherapy.

[45]  D. H. Burke,et al.  HIV-1 inactivation by nucleic acid aptamers. , 2006, Frontiers in bioscience : a journal and virtual library.

[46]  S. Hubchak,et al.  TGF-beta signal transduction and mesangial cell fibrogenesis. , 2003, American journal of physiology. Renal physiology.

[47]  D. Fishman,et al.  Periostin Secreted by Epithelial Ovarian Carcinoma Is a Ligand for V 3 and V 5 Integrins and Promotes Cell Motility 1 , 2002 .

[48]  K. Horiuchi,et al.  Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.